Our aim is to keep investors and interested parties informed of Uscom news events and announcements
The Uscom BP+ is revolutionising the way we treat hypertension, and supporting The Cardio Clinic and the NPA in the Support Your Local Pharmacy Campaign was a big step towards achieving this goal of changing Cardio Vascular health from reactive to preventative health care.
Uscom announced that the new Uscom BP+ is now eligible for Conformité Européenne
(CE) mark allowing it for retail sale in Europe. This means that the new Uscom BP+ can now be sold into Hospital and Clinical markets in CE jurisdictions. This jurisdiction includes the 28 member states of the EU, plus Iceland, Norway, Liechtenstein, Switzerland and Turkey.
Uscom has secured a strategic investment from Mr Steven Meng, a private investor, and senior pharma executive for $1.755M in a placement of new shares. Mr Meng will bring both his international corporate and management skills to Uscom, including his excellent distribution contacts in China.
Uscom has received $492K from the Australian Tax Office under the Federal Government Research and Development (R&D) Tax Incentive Program related to R&D expenditure in the 2017 tax year. The Federal Government R&D program provides for the refund of 43.5% of eligible research and development expenditure during the previous financial year.
